Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Drops By 25.6%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 27,307 shares, a decrease of 25.6% from the December 31st total of 36,688 shares. Based on an average daily volume of 95,930 shares, the short-interest ratio is presently 0.3 days. Currently, 0.5% of the shares of the company are sold short. Currently, 0.5% of the shares of the company are sold short. Based on an average daily volume of 95,930 shares, the short-interest ratio is presently 0.3 days.

Revelation Biosciences Stock Performance

REVB stock traded up $0.13 during midday trading on Friday, hitting $2.03. 423,945 shares of the stock were exchanged, compared to its average volume of 1,690,773. Revelation Biosciences has a fifty-two week low of $1.78 and a fifty-two week high of $55.20. The stock’s 50-day moving average price is $3.50 and its 200-day moving average price is $6.15. The stock has a market cap of $3.21 million, a price-to-earnings ratio of -0.02 and a beta of -0.11.

Revelation Biosciences (NASDAQ:REVB) last posted its earnings results on Thursday, November 6th. The company reported ($7.08) EPS for the quarter, missing analysts’ consensus estimates of ($5.36) by ($1.72). Research analysts anticipate that Revelation Biosciences will post -49.33 EPS for the current year.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently bought a new position in Revelation Biosciences stock. Armistice Capital LLC purchased a new stake in Revelation Biosciences, Inc. (NASDAQ:REVB) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 80,000 shares of the company’s stock, valued at approximately $114,000. Armistice Capital LLC owned 0.52% of Revelation Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Revelation Biosciences in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Revelation Biosciences presently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.